Mapi Pharma Files for IPO

Mapi Pharma of Israel, a company that develops API and intermediates, filed for a $46 million IPO on NASDAQ. The company has a China R&D operation in Nanjing’s NJUT Science and Technology Industrial Park, in addition to its facilities in Israel and Germany. Mapi develops complex APIs and improved delivery formulations for generic drugs. Its lead product is a once-monthly version of Copaxone, an MS treatment produced by Teva. More details.... Stock Symbol: (NYSE: TEVA) Share this with colleagues: // //